Impella CP® in Myocardial Infarction with Cardiogenic Shock: First Evidence in Over 20 Years
This international, multicenter clinical trial (DanGer study) evaluates the effects of routine implantation of the microaxial flow pump (Impella CP®) compared to conventional treatment in patients with acute myocardial infarction complicated by cardiogenic shock.